Marisa Wexler, MS,  senior science writer—

People with multiple sclerosis (MS) have high levels of toxic compounds made by gut bacteria in the fluid around their brain and spinal cord, a study found. “This work not only furthers our understanding of the role of gut-brain communication in neurodegenerative disease progression, but also provides a potential…

A decision by the U.S. Court of Appeals for the Federal Circuit has upheld the validity of a patent for dosing Novartis’ oral multiple sclerosis (MS) treatment Gilenya (fingolimod), the medication’s manufacturer announced. “With this decision, Novartis confirms that it expects no generic versions of Gilenya in the…

A new machine learning algorithm — designed to analyze healthcare records — could help in diagnosing multiple sclerosis (MS) sooner by identifying patients’ symptoms earlier. The algorithm, devised by scientists at the University of California San Francisco (UCSF), was described in a study titled “Embedding electronic health records…

Being a lifelong musician can help protect certain tracts of the brain’s white matter from damage during aging, potentially warding off conditions such as multiple sclerosis, Parkinson’s disease, or dementia for years. That’s according to the study “Effects of Lifelong Musicianship on White Matter Integrity…

Multiple Sclerosis News Today brought you daily coverage of the latest scientific research, advances in treatment, and clinical trials related to multiple sclerosis (MS) throughout 2021. We look forward to continuing to be a resource for the MS community in 2022. Here are the Top 10 most-read articles of…

MS-STAT2, a clinical trial testing whether the cholesterol-lowering medication simvastatin might slow disability progression in secondary progressive multiple sclerosis (SPMS), has finished enrollment. A total of 964 people are now in the trial (NCT03387670), making it the largest progressive MS trial not run by a commercial…

Certain treatments for multiple sclerosis (MS) — specifically, anti-CD20 antibody therapies and Gilenya (fingolimod) — are likely to reduce the effectiveness of vaccines for COVID-19, according to a new study. “Highlighting groups who have mounted an inadequate vaccine response has already been helpful in guiding who should receive…

There is minimal evidence that the expensive anti-inflammatory medication Acthar Gel (repository corticotropin injection) is more effective than inexpensive corticosteroids for the treatment of multiple sclerosis (MS) and other diseases, according to a new review paper. “We found no evidence where it was a conclusive slam dunk that…

Leaders of the International Progressive MS Alliance have proposed a global research strategy to find better ways to care for people with progressive forms of multiple sclerosis (MS). They detailed their proposal in the paper, “Charting a global research strategy for progressive MS—An international progressive MS…

Children and young adults who spend more time outdoors in the sunshine are less likely to develop multiple sclerosis (MS), according to a new study, which suggests that sunshine might help to protect against the disease. “Advising regular time in the sun of at least 30 minutes daily especially…

An imaging technique called optical coherence tomography (OCT) could be useful for monitoring nervous system damage in people with multiple sclerosis (MS), especially early on in the disease, a study in patients reports. The study, “Optical coherence tomography in multiple sclerosis: A 3-year prospective multicenter study,”…

The National MS Society has announced it is funding 13 new research projects that seek to better understand the risk factors involved in multiple sclerosis (MS) development and progression. The funding — nearly $7 million in total — also will go to “rescue” 22 MS-related research projects that…

Tecfidera (dimethyl fumarate) and Aubagio (teriflunomide) are the preferred disease-modifying treatments for managing relapsing-remitting multiple sclerosis (RRMS) in Canada, according to a report from Spherix Global Insights. The report was part of Spherix’s RealTime Dynamix: Multiple Sclerosis (Canada) service, which collects data on market trends of MS…

While older multiple sclerosis (MS) patients whose conditions are stable commonly stop using disease-modifying therapies (DMTs), a study indicates this decision can shortly lead to a marked disease worsening in a substantial portion of them. “Our results raise important questions about the accepted practice of discontinuing medications once MS…

A class of immune-suppressing medications called TNF-alpha inhibitors can reduce the efficacy of vaccines for COVID-19, according to a study that included patients with multiple sclerosis (MS) and other autoimmune diseases. The results also suggest that a third dose of a COVID-19 vaccine may help to protect patients with…

Certain cell therapies that hold promise for treating autoimmune diseases like multiple sclerosis might work not because of the way the cells live in the body during treatment, but because of how they die. A better understanding of how these cell therapies work “is important in designing treatment protocols…

Immunic Therapeutics has enrolled the first participant in its Phase 3 ENSURE clinical trial program, which is testing the company’s investigational treatment IMU-838 (vidofludimus calcium) in people with relapsing-remitting multiple sclerosis (RRMS). “Enrollment of the first patient in ENSURE … marks an important inflection point for Immunic as we…

Cholesterol made by neurons is crucial for repairing long-term damage to the myelin sheath, the fatty coating around nerve fibers that is damaged in multiple sclerosis (MS), according to a new report based on experiments done on mice. The finding suggests that increasing neuronal cholesterol synthesis may be helpful…

The oral medication Vumerity (diroximel fumarate) has been approved by the European Commission to treat adults with relapsing-remitting multiple sclerosis (RRMS). “This approval is a significant step forward in improving treatment adherence for people living with relapsing MS, which can make a meaningful difference on treatment…

Measuring levels of the protein serum neurofilament light chain (NfL) can help to identify people with relapsing-remitting multiple sclerosis (RRMS) at higher risk of relapse-free disability progression or conversion to secondary-progressive disease, according to a study from Germany. The study, “NfL predicts relapse-free progression in a longitudinal…

The multiple sclerosis (MS) treatment Tecfidera (dimethyl fumarate) triggers immune cell death by interacting with a protein called Keap-1, a new study reveals. The study, “Wdr1 and cofilin are necessary mediators of immune-cell-specific apoptosis triggered by Tecfidera,” was published in Nature Communications. Tecfidera is widely…

Ocrevus (ocrelizumab) continues to be the most commonly prescribed therapy for progressive forms of multiple sclerosis (MS), including primary progressive MS (PPMS) and secondary progressive MS (SPMS), according to an analysis from the market intelligence firm Spherix Global Insights. However, other therapies are “gaining traction” among…

Among people with nervous system damage indicative of multiple sclerosis (MS), but who don’t yet have the disease — a condition known as radiologically isolated syndrome or RIS — the risk of progressing to full-fledged MS is higher for those who are younger, have spinal cord lesions, and have…

Not drinking alcohol significantly increases the risk of developing multiple sclerosis (MS), especially if a person also is a current or former smoker, according to a new study. These findings add to the knowledge, discovered in multiple previous studies, that alcohol decreases the activity of the immune system. According…

This year’s Women Against Multiple Sclerosis (WAMS) Gala, which aims to raise funds for multiple sclerosis (MS) research, will take place Nov. 5. In order to keep participants safe in the setting of the ongoing pandemic, the MS Society of Canada‘s initiative will feature three events held virtually:…

People who contract infectious mononucleosis — colloquially known as “mono” — during childhood or adolescence are at a roughly two to three times greater risk of developing multiple sclerosis (MS) as adults, a large population-based study suggests. Notably, the study points to mono itself — independent of other factors…

Colder ambient temperatures may ease the inflammation that drives multiple sclerosis (MS), early research in a mouse model suggests. Animals whose environment for two weeks was set at 10 C (about 50 F) had a “pronounced attenuation” of disease severity and other benefits compared with those kept at a…

Black and Hispanic/Latinx people with multiple sclerosis (MS) in the U.S. tend to have more severe disease, but less access to specialty care, greater diagnostic delays, and poorer outcomes, a review found. Moreover, Blacks are at higher risk than whites of both developing MS and dying from it. These…

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. Certain types of…

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. A…